Results 71 to 80 of about 95,261 (258)

Anti‐Apoptotic and Neurite‐Protective Nanomedicine Augments Embryonic Stem Cells‐Derived Retinal Ganglion Cell Transplantation in Glaucoma Recovery

Advanced Science, EarlyView.
Lithium‐epigallocatechin gallate nanoparticles (Li‐EGCG NPs) are co‐transplanted with embryonic stem cell‐derived retinal ganglion cells (ESC‐RGCs) to enhance cell survival and therapeutic efficacy in an acute pathological glaucomatous injury model. This synergistic approach protects RGC cells, preserves retinal structure and improves visual function ...
Moxin Chen, Xiaoyan Jiang, Yuanhui Wang, Zhaobin Luo, Yu Zhang, Siwei Liu, Rui Huang, Dandan Zhang, Zhimin Tang, Yahan Ju, Shaohui Pan, Ni Ni, Wei Feng, Yu Chen, Ping Gu   +14 more
wiley   +1 more source

Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line

BMC Cancer, 2006
Background Bcl-2 and Bcl-XL are anti-apoptotic paralogues that inhibit apoptosis elicited by a wide variety of stimuli, and play critical roles in cancer development and resistance to treatment.
Leber Brian, Hollerbach Catherine, Zhu Weijia, Fiebig Aline A, Andrews David W   +4 more
doaj   +1 more source

Bcl-xL DNAzymes promote radiosensitivity and chemosensitivity in colorectal cancer cells via enhancing apoptosis

BMC Pharmacology and Toxicology, 2022
Background RNA-cleaving deoxyribozymes (DNAzymes) are catalytic deoxyribonucleic acid molecules that have become a promising new class of gene suppressors by binding and cleaving target mRNA.
Zhen Yu, Jun Guo, Tao Meng, Lei Ge, Lin Liu, Haijiang Wang, Xinhui Yang   +6 more
doaj   +1 more source

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming. [PDF]

, 2016
The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor ...
Bagai, Rakesh, Bivona, Trever G, Danielpour, David, Feng, Yan, Leahy, Patrick, Lindner, Daniel, Ma, Patrick C, Rosell, Rafael, Shi, Ivy, Thiagarajan, Praveena S, Veigl, Martina, Wu, Xiaoliang, Yin, Lihong, Zhang, Wei, Zhang, Zhenfeng   +14 more
core   +1 more source

Bcl‐xL interrupts oxidative activation of neutral sphingomyelinase

FEBS Letters, 2002
Recent studies demonstrate a role for intracellular oxidation in the regulation of neutral sphingomyelinase (N‐SMase). Glutathione (GSH) has been shown to regulate N‐SMase in vitro and in cells. However, it has not been established whether the effects of GSH in cells are due to direct action on N‐SMase.
Okamoto, Yasuo, Obeid, Lina M, Hannun, Yusuf A   +2 more
openaire   +2 more sources

Regulation of Bcl-xl Channel Activity by Calcium [PDF]

Journal of Biological Chemistry, 1998
Recent studies have demonstrated that the anti-apoptotic proteins, Bcl-2 and Bcl-xl, with the carboxyl-terminal hydrophobic domain removed, form cation-selective channels in the lipid bilayer reconstitution system. However, the regulatory properties of these channels are unknown.
M, Lam, M B, Bhat, G, Nuñez, J, Ma, C W, Distelhorst   +4 more
openaire   +2 more sources

A Modular DNAzyme for Precise Visualization and Intervention of Alternative Splicing Isoforms in Live Cells

Advanced Science, EarlyView.
A Stringent dUPlex‐activated Error Robust (SUPER) DNAzyme system enables real‐time imaging of alternative mRNA splicing (e.g., Bcl‐xL/Bcl‐xS) in living cells via target‐triggered split‐DNAzyme reassembly and dual‐color fluorescence. It also achieves mRNA‐selective knockdown through DNAzyme‐based gene regulation, serving as a versatile tool for splicing
Mengru Lin, Jiale Sun, Yuqing Mao, Yuhao Tang, Fuan Wang, Zhihong Liu, Jing Wang   +6 more
wiley   +1 more source

BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. [PDF]

PLoS ONE, 2014
Bcl-2 and Bcl-xL are critical regulators of apoptosis that are overexpressed in a variety of human cancers and pharmacological inhibition of Bcl-2 and Bcl-xL represents a promising strategy for cancer treatment.
Longchuan Bai, Jianfang Chen, Donna McEachern, Liu Liu, Haibin Zhou, Angelo Aguilar, Shaomeng Wang   +6 more
doaj   +1 more source

Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells [PDF]

, 2010
Inhibition or downregulation of Bcl-2 represents a new therapeutic approach to by-pass chemoresistance in cancer cells. Therefore, we explored the potential of this approach in breast cancer cells.
A Letai, AK Zimmermann, Cagri Bodur, D Moon, D Tian, Dilek Telci, DJ Stewart, Elif Damla Arisan, F Manero, FA Sinicrope, Huveyda Basaga, IJ Enyedy, J An, J Chen, J Skommer, J Yu, JC Reed, JD Lickliter, JI Okani, JL Wang, JL Wang, L Chen, L Ming, L Oliver, M Milella, Ozgur Kutuk, RK Srivastava, SW Lowe, Tugsan Tezil, X Pei, X Wang, XY Pei, Y Ling, Y Su, Z Liu   +34 more
core   +1 more source

A Bcl-xL Timer Sets Platelet Life Span [PDF]

Cell, 2007
Platelets are cell fragments lacking nuclei that play a key role in blood clotting. Using an impressive genetic screen involving ENU-mutagenesis of whole mice, Mason et al. (2007) report in this issue their identification of mutations in the antiapoptotic protein Bcl-x(L) that cause accelerated death of platelets leading to platelet deficiency.
Qi, Bing, Hardwick, J. Marie
openaire   +2 more sources